10 likes | 116 Views
RIT Panel
E N D
RIT Panel S. Rupoli, A.Tassetti , N. Cantore, F. Palmieri, V. Liso, G. Specchia, P.Carluccio, C. Cristofalo, C. Gasbarrino, P. Ditonno, E. DE Biasi, E. Cacciola, R. Cacciola, R. Centurioni, A. Inzoli, P. Spedini, A. Bosi, A. M. Vannucchi, E. Antonioli, A. Grossi, F. Balestri, G. Beltrami, R. Bruni, M. Gobbi, I. Pierri, C. Musolino, C. Alati, F. Lussana, S. Caberlon, F. Zallio, P. Mannucci, P. Bucciarelli, A. Zanella, F. Radaelli, A. Iurlo, G. Leonardi, M. Morucci, L. Mastrullo, F. Gonnella, M.R. Villa, D. De Blasi, V. Martinelli, R. Ciancia, G. Gaidano, S. Franceschetti, G. Saglio, D. Cilloni, F. Fabris, M.L. Randi, F. Porretto, M. Crugnola, F. Passamonti, E. Rumi, G. Davì, A. Dragani, E. Orciuolo, G. O. Manenti, G. Garozzo, M. Salvucci, L. Gugliotta, A. Tieghi, C. Musto, L. Maurillo, M. De Muro, M. Cedrone, R. Foà, M. G. Mazzucconi, R. Latagliata, C. Santoro, F. Saltarelli, L. Siracusano, F. Ardizzone, M. Iovine, N. Cascavilla, R. P. Scalzulli, L. Melillo, M. Balboni, A. Candoni, F. Rodeghiero, M. Ruggeri, G. Castaman. RIT Institutions • •Alessandria • • Ancona • •Ascoli Piceno • •Avellino • •Bari • •Bologna • •Bolzano • •Brindisi • •Cagliari • •Campobasso • •Carbonara di Bari • •Castelfranco Veneto • •Catania • •Catanzaro • •Civitanova Marche • •Como • •Cosenza • •Crema • •Cremona • •Firenze • •Firenze Ist.L.da Vinci • •Genova S.Martino • •Genova DIMI • •Genova Ematologia I • •L’Aquila • •La Spezia •Mantova •Matera •Messina Papardo •Messina Policlinico •Milano S.Paolo •Milano Ist. Tumori •Milano Policlinico •Milano S. Raffaele •Milano Ematologia II •Modena •Montefiascone •Monza •Napoli S.Gennaro •Napoli S.G.Bosco •Napoli Federico II •Nocera Inferiore •Novara •Orbassano •Padova •Palermo La Maddalena •Parma •Pavia Clinica Med.III •Pavia Ematologia •Perugia •Pesaro •Pescara • •Piacenza • •Pisa • •Pordenone • •Ragusa • •Ravenna • •Reggio Calabria • •Reggio Emilia • •Rionero in Vulture • •Roma S.G.Addolorata • •Roma Osp. San Giacomo • •Roma La Sapienza • •Roma Gemelli • •Roma Tor Vergata • •Roma S.Eugenio • •Roma S.Spirito • • Roma Campus Biomedico • • Roma A.O. Sant’Andrea • •Rozzano • S.Felice a Cancello • •S.Giovanni Rotondo • •Siena • •Sondalo • •Torino • •TorinoM • •Udine • •Vicenza Characteristic at diagnosis PATIENTS 767 PREVIOUS THROMBOSIS Major 4 % 2 % PREVIOUS HEMORRHAGE 1 % SYMPTOMS 42 % THROMBOTIC RISK FACTORS 69 % SPLENOMEGALY 25 % PREGNANCIES 60 ASPIRIN 70% CYTOREDUCTION Hydroxyurea Anagrelide Interferons Pipobroman Busulfan 63% 61% 12% 11% 4% 2% True ET (WHO criteria) 27% Normal KARYOTYPE 274 / 274 THE REGISTRO ITALIANO TROMBOCITEMIE (RIT): PRELIMINARY ANALYSIS OF THE FIRST 767 ENROLLED PATIENTS L.Gugliotta and A. Tieghi for the RIT Panel * Results • Background • The Registro Italiano Trombocitemie (RIT) is a web- based registry • for the collection of clinical and biological data in ET patients. • The RIT is a project approved and supported by the GIMEMA • (Gruppo Italiano Malattie Ematologiche dell’Adulto) • Aims • •To registry ET patients observed in the italian Institutions. • •To validate the diagnosis appropriateness (WHO criteria) by performing • a centralized revision of the bone marrow biopsies • •To promote the acquisition of biological data (clonality, JAK2 mutation, haemostasis) • •To evaluate the compliance to the therapeutical guide lines of the Italian Society of Haematology • •To monitor the ET patients receiving Interferons alpha or Anagrelide • •To evaluate cases of pregnancy, pediatric age and familiarity • •To create a network for activation of new clinical and biological studies • Methods • The RIT, co-ordinated by the Haematology Unit of Reggio Emilia, is a web-based registry (www.trombocitemie.it) that, besides a public area, comprehends a database of italian ET patients. • The data, with respect of the privacy rules, are object of validation and analysis by various RIT Expert Subcommittees. 767 Patients 78 Centers Concluding Remarks · The majority of the italian Haematological Centers are registering ET patients into the RIT. ·The preliminary analysis of the 767 registered patients shows that in 92% of patients the diagnosis was done according to the PVSG criteria. · In the ET patients, classified according to the WHO criteria, the rate of True ET ( 27%) was similar to that reported in other patient series · The ongoing revision of the bone marrow biopsies will permit a reclassification according to the WHO criteria. · Improvement of the diagnostic approach is expected and the harvest of biological material as been activated. · A separate analysis is ongoing for specific series of patients treated with Anagrelide and Iterferons alpha.